Prelude Therapeutics to Pause Development of Cancer Drug

Dow Jones11-04

By Nicholas G. Miller

Prelude Therapeutics is pausing development in one of its cancer drug programs and will prioritize other programs, the company said Tuesday.

The company will pause clinical development of its SMARCA2 selective degrader programs, saying it does not have the resources to explore the biologically complex mechanism fully in the timeframe needed.

Prelude said it will prioritize development of its mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs.

The company said Tuesday it made an exclusive option agreement with Incyte to advance its mutant selective JAK2V617F JH2 inhibitor program for patients with myeloproliferative neoplasms.

Through the agreement, Prelude will receive an upfront payment of $35 million, a $25 million equity investment and $100 million if the option is exercised.

Prelude said its cash runway is now expected to extend into 2027 and could extend into the third quarter of 2028 if Incyte exercises its option.

The company is also eligible to receive up to $775 million in additional potential milestones plus royalties on net sales.

Prelude also said President and Chief Medical Officer Jane Huang was leaving the company to pursue other opportunities.

The company's shares are down 20% in pre-market trading to $3.18.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

November 04, 2025 07:50 ET (12:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580313997?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580313997","market":"sg","top_or_hot":-1,"title":"Prelude Therapeutics to Pause Development of Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is pausing development in one of its cancer drug programs and will prioritize other programs, the company said Tuesday. \n</p>\n<p>\n  The company will pause clinical development of its SMARCA2 selective degrader programs, saying it does not have the resources to explore the biologically complex mechanism fully in the timeframe needed. \n</p>\n<p>\n  Prelude said it will prioritize development of its mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs. \n</p>\n<p>\n  The company said Tuesday it made an exclusive option agreement with Incyte to advance its mutant selective JAK2V617F JH2 inhibitor program for patients with myeloproliferative neoplasms. \n</p>\n<p>\n  Through the agreement, Prelude will receive an upfront payment of $35 million, a $25 million equity investment and $100 million if the option is exercised. \n</p>\n<p>\n  Prelude said its cash runway is now expected to extend into 2027 and could extend into the third quarter of 2028 if Incyte exercises its option. \n</p>\n<p>\n  The company is also eligible to receive up to $775 million in additional potential milestones plus royalties on net sales. \n</p>\n<p>\n  Prelude also said President and Chief Medical Officer Jane Huang was leaving the company to pursue other opportunities. \n</p>\n<p>\n  The company's shares are down 20% in pre-market trading to $3.18. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2025 07:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prelude Therapeutics to Pause Development of Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrelude Therapeutics to Pause Development of Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-04 20:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is pausing development in one of its cancer drug programs and will prioritize other programs, the company said Tuesday. \n</p>\n<p>\n  The company will pause clinical development of its SMARCA2 selective degrader programs, saying it does not have the resources to explore the biologically complex mechanism fully in the timeframe needed. \n</p>\n<p>\n  Prelude said it will prioritize development of its mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs. \n</p>\n<p>\n  The company said Tuesday it made an exclusive option agreement with Incyte to advance its mutant selective JAK2V617F JH2 inhibitor program for patients with myeloproliferative neoplasms. \n</p>\n<p>\n  Through the agreement, Prelude will receive an upfront payment of $35 million, a $25 million equity investment and $100 million if the option is exercised. \n</p>\n<p>\n  Prelude said its cash runway is now expected to extend into 2027 and could extend into the third quarter of 2028 if Incyte exercises its option. \n</p>\n<p>\n  The company is also eligible to receive up to $775 million in additional potential milestones plus royalties on net sales. \n</p>\n<p>\n  Prelude also said President and Chief Medical Officer Jane Huang was leaving the company to pursue other opportunities. \n</p>\n<p>\n  The company's shares are down 20% in pre-market trading to $3.18. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2025 07:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580313997","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580313997","pubTimestamp":1762260600,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Prelude Therapeutics is pausing development in one of its cancer drug programs and will prioritize other programs, the company said Tuesday.The company will pause clinical development of its SMARCA2 selective degrader programs, saying it does not have the resources to explore the biologically complex mechanism fully in the timeframe needed.Prelude said it will prioritize development of its mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs.The company said Tuesday it made an exclusive option agreement with Incyte to advance its mutant selective JAK2V617F JH2 inhibitor program for patients with myeloproliferative neoplasms.Through the agreement, Prelude will receive an upfront payment of $35 million, a $25 million equity investment and $100 million if the option is exercised.Prelude said its cash runway is now expected to extend into 2027 and could extend into the third quarter of 2028 if Incyte exercises its option.The company is also eligible to receive up ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","PRLD":"Prelude Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Prelude Therapeutics暂停癌症药物开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRLD":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Prelude Therapeutics is pausing development in one of its cancer drug programs and will prioritize other programs, the company said Tuesday. \n\n\n  The company will pause clinical development of its SMARCA2 selective degrader programs, saying it does not have the resources to explore the biologically complex mechanism fully in the timeframe needed. \n\n\n  Prelude said it will prioritize development of its mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs. \n\n\n  The company said Tuesday it made an exclusive option agreement with Incyte to advance its mutant selective JAK2V617F JH2 inhibitor program for patients with myeloproliferative neoplasms. \n\n\n  Through the agreement, Prelude will receive an upfront payment of $35 million, a $25 million equity investment and $100 million if the option is exercised. \n\n\n  Prelude said its cash runway is now expected to extend into 2027 and could extend into the third quarter of 2028 if Incyte exercises its option. \n\n\n  The company is also eligible to receive up to $775 million in additional potential milestones plus royalties on net sales. \n\n\n  Prelude also said President and Chief Medical Officer Jane Huang was leaving the company to pursue other opportunities. \n\n\n  The company's shares are down 20% in pre-market trading to $3.18. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 07:50 ET (12:50 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580313997","isCrawlerRequest":true}